medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2023-11-35-43medalphabet-3149Research ArticleСтатьиПроявления местной и системной реактогенности вакцин, используемых для вакцинации против новой коронавирусной инфекцииManifestations of excessive and systemic reactogenicity of vaccine, requirements for vaccination against new coronavirus infectionhttps://orcid.org/0000-0001-7786-3777МедведеваЕ. А.MedvedevaE. A.

Медведева Евгения Александровна, к.м.н., ассистент кафедры пропедевтики внутренних болезней и гастроэнтерологии

Author ID: 950179

Москва

Medvedeva Evgenia A., PhD Med, assistant at Dept of Propaedeutics of Internal Diseases and Gastroenterology

Author ID: 950179

Moscow

evgeniya0103med@yandex.ruhttps://orcid.org/0000-0003-3385-2632ЗыковК. А.ZykovK. A.

Зыков Кирилл Алексеевич, д.м.н., проф., член-корр. РАН, зам. директора по научной и инновационной работе

Author ID: 600343, Scopus: 26538429700

Москва

Zykov Kirill A., DM Sci (habil.), professor, corresponding member of RAS, deputy director for scientific and innovative works

Author ID: 600343, Scopus: 26538429700

Moscow

https://orcid.org/0000-0002-3612-1889ПлоскиреваА. А.PloskirevaA. A.

Плоскирева Антонина Александровна, д.м.н., проф. РАН, зам. директора по клинической работе

Author ID: 625678, Scopus AuthorID: 56848285800

Москва

Ploskireva Antonina A., DM Sci (habil.), professor of RAS, deputy director for clinical works

Author ID: 625678, Scopus AuthorID: 56848285800

Moscow

https://orcid.org/0000-0003-2179-8421МарьинГ. Г.MaryinG. G.

Марьин Герман Геннадьевич, д.м.н., проф. кафедры эпидемиологии

Author ID: 686015

Москва

Maryin German G., DM Sci (habil.), professor at Dept of Epidemiology

Author ID: 686015

Moscow

ger-marin@yandex.ruhttps://orcid.org/0000-0003-1757-8389СвитичО. А.SvitichO. A.

Свитич Оксана Анатольевна, д.м.н., проф., член-корр. РАН, директор

Author ID: 638598

Москва

Svitich Oksana A., DM Sci (habil.), professor, corresponding member of RAS, director

Author ID: 638598

Moscow

svitichoa@yandex.ruhttps://orcid.org/0000-0001-8181-8813ЮреневГ. Л.YurenevG. L.

Юренев Георгий Леонидович, д.м.н., проф. кафедры пропедевтики внутренних болезней и гастроэнтерологии

Author ID: 487460, Scopus: 6506044575

Москва

Yurenev Georgy L., DM Sci (habil.), professor at Dept of Propaedeutics of Internal Diseases and Gastroenterology

Author ID: 487460, Scopus: 6506044575

Moscow

https://orcid.org/0000-0001-9154-7017КузинА. А.KuzinA. A.

Кузин Александр Александрович, д.м.н., проф., полковник медицинской службы, начальник кафедры (общей и военной эпидемиологии)

Author ID: 358877

Санкт-Петербург

Kuzin Aleksandr A., DM Sci (habil.), professor, colonel of the medical service, head of Dept (General and Military Epidemiology)

Author ID: 358877

Saint Petersburg

paster-spb@mail.ruhttps://orcid.org/0000-0001-7791-8993ЗобовА. Е.ZobovA. E.

Зобов Андрей Евгеньевич, к.м.н., преподаватель кафедры (общей и военной эпидемиологии), подполковник медицинской службы

Author ID: 822170

Санкт-Петербург

Zobov Andrey E., PhD Med, lecturer at Dept (General and Military Epidemiology), lieutenant colonel of the medical service

Author ID: 822170

Saint Petersburg

dr.andrey98@yandex.ruНазаровД. А.NazarovD. A.

Назаров Дмитрий Александрович, зам. главного врача по лечебной работе

Author ID: 1132532

Москва

Nazarov Dmitry A., deputy chief physician for medical work

Author ID: 1132532

Moscow

ВолынковИ. О.VolynkovI. O.

Волынков Игорь Олегович, начальник санитарно-эпидемиологического отделения

Author ID: 1089518

Москва

Volynkov Igor O., head of Sanitary and Epidemiological Dept

Author ID: 1089518

Moscow

gvkgsed@rambler.ruhttps://orcid.org/0000-0002-1309-4005КубышкинА. В.KubyshkinA. V.

Кубышкин Анатолий Владимирович, д.м.н., проф., зав. кафедрой общей и клинической патофизиологии, проректор по научной деятельности

Scopus: 7004172980, Author ID: 671210

г. Симферополь, Республика Крым

Kubyshkin Anatoly V., DM Sci (habil.), professor, head of Dept of General and Clinical Pathophysiology, vice-rector for research

Scopus: 7004172980, Author ID: 671210

Simferopol, Republic of Crimea

https://orcid.org/0000-0002-6607-3793ЧеботареваТ. А.ChebotarevaT. A.

Чеботарева Татьяна Алексеевна, д.м.н., проф., проф. кафедры детских инфекционных болезней

Москва

Chebotareva Tatyana A., DM Sci (habil.), professor, professor at Dept of Children’s Infectious Diseases

Moscow

https://orcid.org/0000-0002-0099-3036РомановаК. Г.RomanovaK. G.

Романова Ксения Германовна, врач

Москва

Romanova Ksenia G., physician

Moscow

ФГБОУ ВО «Московский государственный медико-стоматологический университет имени А.И. Евдокимова» Минздрава РоссииРоссияMoscow State University of Medicine and Dentistry n.a. A.I. EvdokimovRussian FederationФГБОУ «Научно-исследовательский институт пульмонологии» ФМБА РоссииРоссияResearch Institute of PulmonologyRussian FederationФБУН «Центральный научно-исследовательский институт эпидемиологии» РоспотребнадзораРоссияCentral Research Institute of EpidemiologyRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России; Отделение медицинских наук Российской академии наукРоссияRussian Medical Academy for Continuing Professional Education; Department of Medical Sciences of Russian Academy of SciencesRussian FederationФГБУ «Научно-исследовательский институт вакцин и сывороток имени И.И. Мечникова» Российской академии наукРоссияScientific and Research Institute for Vaccines and Sera n.a. I.I. MechnikovRussian FederationФГБВОУ ВО «Военно-медицинская академия имени С. М. Кирова» Минобороны РоссииРоссияMilitary Medical Academy n.a. S.M. KirovRussian FederationФГБУ «Главный военный клинический госпиталь имени академика Н.Н. Бурденко» Минобороны РоссииРоссияMain Military Clinical Hospital n.a. academician N.N. Burdenko of the Ministry of Defense of RussiaRussian FederationФГАОУ ВО «Крымский федеральный университет имени В.И. Вернадского»РоссияCrimean Federal University n.a. V.I. VernadskyRussian FederationФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава РоссииРоссияRussian Medical Academy for Continuing Professional EducationRussian FederationФГБУ «Национальный медицинский исследовательский центр оториноларингологии ФМБА РоссииРоссияNational Medical Research Center for OtorhinolaryngologyRussian Federation202328062023011Обозрение (1)3543Copyright © Медведева Е.А., Зыков К.А., Плоскирева А.А., Марьин Г.Г., Свитич О.А., Юренев Г.Л., Кузин А.А., Зобов А.Е., Назаров Д.А., Волынков И.О., Кубышкин А.В., Чеботарева Т.А., Романова К.Г., 20232023Медведева Е.А., Зыков К.А., Плоскирева А.А., Марьин Г.Г., Свитич О.А., Юренев Г.Л., Кузин А.А., Зобов А.Е., Назаров Д.А., Волынков И.О., Кубышкин А.В., Чеботарева Т.А., Романова К.Г.Medvedeva E.A., Zykov K.A., Ploskireva A.A., Maryin G.G., Svitich O.A., Yurenev G.L., Kuzin A.A., Zobov A.E., Nazarov D.A., Volynkov I.O., Kubyshkin A.V., Chebotareva T.A., Romanova K.G.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/3149Вступление

Вступление. Новая коронавирусная инфекция (COVID-19) привела не только к пандемии, сопровождавшейся высокой летальностью, большому спросу на применение различных лекарственных препаратов, но и к беспрецедентно быстрому созданию вакцин. С целью снижения темпов распространения инфекции, тяжести течения заболевания, в ряде стран в 2021 году вакцины против COVID-19 получили одобрение для практического применения. Доказано, что вакцины против SARS-CoV-2 являются безопасным и эффективным средством борьбы против этой инфекции. При применении всех видов вакцин могут возникать различные побочные и нежелательные эффекты. Реакции на вакцинацию против COVID-19 обычно слабые или средней силы и, как правило, кратковременны.

Цель обзора

Цель обзора. Охарактеризовать основные побочные и нежелательные эффекты, зарегистрированные в течение 20 месяцев после одобрения ВОЗ вакцинации против SARS-CoV-2.

Материалы и методы

Материалы и методы. Проведен анализ литературы из различных баз данных, включая PubMed, ВОЗ. Ключевыми используемыми терминами при поиске литературы были: коронавирус, SARS-CoV-2, пандемия COVID-19, вакцины, вакцина и побочные и нежелательные эффекты. В обзор включены 38 источников, в том числе исследовательские статьи, клинические испытания и обзоры литературы.

Заключение

Заключение. Результаты представленного обзора могут быть использованы в качестве дополнительного инструмента при планировании сравнительных исследований эффективности и безопасности вакцинопрофилактики против COVID-19.

Introduction

Introduction. The new coronavirus infection (COVID-19) has led not only to a pandemic accompanied by high mortality, a great demand for the use of various drugs, but also to an unprecedented rapid development. In order to reduce the rate of infection spread and the severity of the course of the disease, COVID-19 vaccines were approved for practical use in a number of countries in 2021. Vaccines against SARS-CoV-2 have been proven to be safe and effective against this infection. However, with all types of vaccines, various side and unwanted effects may occur. Reactions to COVID-19 vaccination are usually mild to moderate and are usually short-lived.

Objective

Objective. To characterize the main adverse and adverse effects reported within 20 months of WHO approval of SARS-CoV-2 vaccination.

Materials and methods

Materials and methods. Literature was analyzed from various databases, including PubMed, WHO. The key terms used in the literature search were: coronavirus, SARS-CoV-2, COVID-19 pandemic, vaccines, vaccine, and adverse and adverse effects. The review includes 38 sources, including research articles, clinical trials, and literature reviews.

Conclusions

Conclusions. The results of the presented review can be used as an additional tool in planning comparative studies of the efficacy and safety of vaccine prevention against COVID-19.

вакцинациякоронавирусная инфекциянежелательные эффектыпобочные эффектыSARS-CoV-2поствакцинальные реакцииvaccinationcoronavirus infectionadverse effectsside effectsSARS-CoV-2ReferencesWilson P, Zumla A. Transmission and prevention of acute viral respiratory tract infections in hospitals. Curr Opin Pulm Med. 2019 May; 25 (3): 220–224. DOI: 10.1097/mcp.0000000000000566. PMID: 30730312. =Wilson P, Zumla A. Transmission and prevention of acute viral respiratory tract infections in hospitals. Curr Opin Pulm Med. 2019 May; 25 (3): 220–224. DOI: 10.1097/mcp.0000000000000566. PMID: 30730312. =Tondo G, Virgilio E, Naldi A, Bianchi A, Comi C. Safety of COVID-19 Vaccines: Spotlight on Neurological Complications. Life (Basel). 2022 Aug 29; 12 (9): 1338. DOI: 10.3390/life12091338. PMID: 36143376; PMCID: PMC 9502976.Tondo G, Virgilio E, Naldi A, Bianchi A, Comi C. Safety of COVID-19 Vaccines: Spotlight on Neurological Complications. Life (Basel). 2022 Aug 29; 12 (9): 1338. DOI: 10.3390/life12091338. PMID: 36143376; PMCID: PMC 9502976.Farnudian-Habibi A, Mirjani M, Montazer V, Aliebrahimi S, Katouzian I, Abdolhosseini S, Rahmani A, Keyvani H, Ostad SN, Rad-Malekshahi M. Review on Approved and Inprogress COVID-19 Vaccines. Iran J Pharm Res. 2022 Jan 24; 21 (1): e124228. DOI: 10.5812/ijpr.124228. PMID: 36060923; PMCID: PMC9420219.Farnudian-Habibi A, Mirjani M, Montazer V, Aliebrahimi S, Katouzian I, Abdolhosseini S, Rahmani A, Keyvani H, Ostad SN, Rad-Malekshahi M. Review on Approved and Inprogress COVID-19 Vaccines. Iran J Pharm Res. 2022 Jan 24; 21 (1): e124228. DOI: 10.5812/ijpr.124228. PMID: 36060923; PMCID: PMC9420219.Wark PA, MacIntyre CR, Bell S, Oliver B, Marks GB. We are not doing enough to prevent the spread of COVID-19 and other respiratory viruses in Australian hospitals. Med J Aust. 2021 Aug 16; 215 (4): 152–153. e1. DOI: 10.5694/mja2.51183. Epub 2021 Jul 21. PMID: 34291464; PMCID: PMC 8447400.Wark PA, MacIntyre CR, Bell S, Oliver B, Marks GB. We are not doing enough to prevent the spread of COVID-19 and other respiratory viruses in Australian hospitals. Med J Aust. 2021 Aug 16; 215 (4): 152–153. e1. DOI: 10.5694/mja2.51183. Epub 2021 Jul 21. PMID: 34291464; PMCID: PMC 8447400.https://стопкоронавирус.рф/news/20210608–1420.htmlhttps://стопкоронавирус.рф/news/20210608–1420.htmlOlsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, Kniss K, Burns E, Rowe T, Foust A, Jasso G, Merced-Morales A, Davis CT, Jang Y, Jones J, Daly P, Gubareva L, Barnes J, Kondor R, Sessions W, Smith C, Wentworth DE, Garg S, Havers FP, Fry AM, Hall AJ, Brammer L, Silk BJ. Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic – United States, 2020–2021. MMWR Morb Mortal Wkly.Olsen SJ, Winn AK, Budd AP, Prill MM, Steel J, Midgley CM, Kniss K, Burns E, Rowe T, Foust A, Jasso G, Merced-Morales A, Davis CT, Jang Y, Jones J, Daly P, Gubareva L, Barnes J, Kondor R, Sessions W, Smith C, Wentworth DE, Garg S, Havers FP, Fry AM, Hall AJ, Brammer L, Silk BJ. Changes in Influenza and Other Respiratory Virus Activity During the COVID-19 Pandemic – United States, 2020–2021. MMWR Morb Mortal Wkly.Киселева И. В., Ларионова Н. В., Григорьева Е. П., Ксенафонтов А. Д., Аль Фаррух М., Руденко Л.Г. Особенности циркуляции респираторных вирусов в пред- и пандемические по гриппу и COVID-19 периоды. Инфекция и иммунитет. 2021. № 6. https://cyberleninka.ru/article/n/osobennosti-tsirkulyatsiirespiratornyh-virusov-v-pred-i-pandemicheskie-po-grippu-i-covid-19-periody (дата обращения: 04.10.2022). Rep. 2021 Jul 23; 70 (29): 1013–1019. DOI: 10.15585/mmwr.mm7029a1. PMID: 34292924; PMCID: PMC 8297694.Kiseleva I. V., Larionova N.V., Grigoryeva E. P., Ksenafontov A.D., Al Farrukh M., Rudenko L. G. Peculiarities of the circulation of respiratory viruses in pre-and pandemic influenza and COVID-19 periods. Infection and immunity. 2021. No. 6. https://cyberleninka.ru/article/n/osobennosti-tsirkulyatsii-respiratornyh-virusov-v-pred-i-pandemicheskie-po-grippu-i-covid-19-periody (date of access: 04.10. 2022). Rep. 2021 Jul 23; 70 (29): 1013–1019. DOI: 10.15585/mmwr.mm7029a1. PMID: 34292924; PMCID: PMC 8297694.Hannah Ritchie, Edouard Mathieu, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser (2020). Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. Retrieved from: https://ourworldindata.org/coronavirus [Online Resource]Hannah Ritchie, Edouard Mathieu, Lucas Rodés-Guirao, Cameron Appel, Charlie Giattino, Esteban Ortiz-Ospina, Joe Hasell, Bobbie Macdonald, Diana Beltekian and Max Roser (2020). Coronavirus Pandemic (COVID-19). Published online at OurWorldInData.org. Retrieved from: https://ourworldindata.org/coronavirus [Online Resource]https://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccineshttps://www.who.int/emergencies/diseases/novel-coronavirus-2019/covid-19-vaccinesПисьмо Минздрава России от 22.12.2021 № 30–4/И/2–21694 «О направлении актуализированных временных методических рекомендаций. Порядок проведения вакцинации против новой коронавирусной инфекции (COVID-19)». Приложение. Временные методические рекомендации. Порядок проведения вакцинации против новой коронавирусной инфекции (COVID-19).Letter of the Ministry of Health of Russia dated December 22, 2021 No. 30–4 /I/2–21694 “On the submission of updated temporary guidelines. The procedure for vaccination against a new coronavirus infection (COVID-19)”. Appendix. Temporary guidelines. The procedure for vaccination against a new coronavirus infection (COVID-19).WHO target product profiles for COVID-19 vaccines. [Электронный ресурс] https://www.who.int/publications/m/item/who-target-product-profiles-forcovid-19-vaccinesюWHO target product profiles for COVID-19 vaccines. [Электронный ресурс] https://www.who.int/publications/m/item/who-target-product-profiles-forcovid-19-vaccinesюAleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). 2022 May 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 34033342.Aleem A, Akbar Samad AB, Slenker AK. Emerging Variants of SARS-CoV-2 And Novel Therapeutics Against Coronavirus (COVID-19). 2022 May 12. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 34033342.Oberemok V.V., Laikova K.V., Yurchenko K.A., Fomochkina I.I., & Kubyshkin A.V. SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship. Inflammation research, 2020, 69 (7), 635–640.Oberemok V.V., Laikova K.V., Yurchenko K.A., Fomochkina I.I., & Kubyshkin A.V. SARS-CoV-2 will continue to circulate in the human population: an opinion from the point of view of the virus-host relationship. Inflammation research, 2020, 69 (7), 635–640.https://pharmmedprom.ru/news/antikovidnaya-vaktsina-r-kovi-ot-astrazeneca-teper-proizvoditsya-v-rossii-dlya-eksporta/https://pharmmedprom.ru/news/antikovidnaya-vaktsina-r-kovi-ot-astrazeneca-teper-proizvoditsya-v-rossii-dlya-eksporta/Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM, Guevara SLR, Echeverría LE, Glisic M, Muka T. COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes. Am J Epidemiol. 2021 Jan 4; 190 (1): 161–175. DOI: 10.1093/aje/kwaa191. Erratum in: Am J Epidemiol. 2021 Jan 4; 190 (1): 187. PMID: 32870978; PMCID: PMC 7499478.Gómez-Ochoa SA, Franco OH, Rojas LZ, Raguindin PF, Roa-Díaz ZM, Wyssmann BM, Guevara SLR, Echeverría LE, Glisic M, Muka T. COVID-19 in Health-Care Workers: A Living Systematic Review and Meta-Analysis of Prevalence, Risk Factors, Clinical Characteristics, and Outcomes. Am J Epidemiol. 2021 Jan 4; 190 (1): 161–175. DOI: 10.1093/aje/kwaa191. Erratum in: Am J Epidemiol. 2021 Jan 4; 190 (1): 187. PMID: 32870978; PMCID: PMC 7499478.WHO target product profiles for COVID-19 vaccination for children [Электронный ресурс]. https://www.who.int/news/item/11–08–2022-interim-statement-oncovid-19-vaccination-for-childrenWHO target product profiles for COVID-19 vaccination for children [Электронный ресурс]. https://www.who.int/news/item/11–08–2022-interim-statement-oncovid-19-vaccination-for-childrenGeurtsvan Kessel, Corine H et al. Evaluating novel COVID-19 vaccines in the current chapter of the pandemic. Lancet Infect Dis 2022 Published Online September 5, 2022 https://doi.org/10.1016/s1473–3099(22)00517–5 SeeOnline. Articles https://doi.org/10.1016/s1473–3099 (22)00502–3Geurtsvan Kessel, Corine H et al. Evaluating novel COVID-19 vaccines in the current chapter of the pandemic. Lancet Infect Dis 2022 Published Online September 5, 2022 https://doi.org/10.1016/s1473–3099(22)00517–5 SeeOnline. Articles https://doi.org/10.1016/s1473–3099 (22)00502–3Ковид-19: самые «болеющие» профессии [Электронный ресурс]. https://35media.ru/articles/2020/11/17/kovid-19-samye-boleyushhie-professii. The impact of COVID-19 on health and care workers: A closer look at deaths.Ковид-19: самые «болеющие» профессии [Электронный ресурс]. https://35media.ru/articles/2020/11/17/kovid-19-samye-boleyushhie-professii. The impact of COVID-19 on health and care workers: A closer look at deaths.WHO The impact of COVID-19 on health and care workers: a closer look at deaths. Working paper 1 [Электронный ресурс]. https://www.who.int/publications/i/item/who-hwf-WorkingPaper-2021.1WHO The impact of COVID-19 on health and care workers: a closer look at deaths. Working paper 1 [Электронный ресурс]. https://www.who.int/publications/i/item/who-hwf-WorkingPaper-2021.1Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2020; (11): CD 006207.Jefferson T, Del Mar CB, Dooley L, et al. Physical interventions to interrupt or reduce the spread of respiratory viruses. Cochrane Database Syst Rev 2020; (11): CD 006207.an Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564–1567an Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382: 1564–1567Bahl P, Doolan C, de Silva C, et al. Airborne or droplet precautions for health workers treating coronavirus disease 2019? J Infect Dis 2020; 10.1093/infdis/jiaa189Bahl P, Doolan C, de Silva C, et al. Airborne or droplet precautions for health workers treating coronavirus disease 2019? J Infect Dis 2020; 10.1093/infdis/jiaa189Santarpia JL, Rivera DN, Herrera VL, et al. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep 2020; 10: 12732.Santarpia JL, Rivera DN, Herrera VL, et al. Aerosol and surface contamination of SARS-CoV-2 observed in quarantine and isolation care. Sci Rep 2020; 10: 12732.Bourouiba L. Images in clinical medicine: a sneeze. N Engl J Med 2016; 375: e15.Bourouiba L. Images in clinical medicine: a sneeze. N Engl J Med 2016; 375: e15.El-Boghdadly K, Wong DJN, Owen R, et al. Risks to healthcare workers following tracheal intubation of patients with COVID-19: A prospective international multicentre cohort study. Anaesthesia 2020; 75: 1437–1447El-Boghdadly K, Wong DJN, Owen R, et al. Risks to healthcare workers following tracheal intubation of patients with COVID-19: A prospective international multicentre cohort study. Anaesthesia 2020; 75: 1437–1447Oksanen L-MAH, Sanmark E, Oksanen S, et al. Healthcare workers high COVID-19 infection rate: the source of infections and potential for respirators and surgical masks to reduce occupational infections [preprint]. medRxiv 2020; 18 Aug; 10.1101/2020.08.17.20176842.Oksanen L-MAH, Sanmark E, Oksanen S, et al. Healthcare workers high COVID-19 infection rate: the source of infections and potential for respirators and surgical masks to reduce occupational infections [preprint]. medRxiv 2020; 18 Aug; 10.1101/2020.08.17.20176842.Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021 Feb; 25 (3): 1663–1669. DOI: 10.26355/eurrev_202102_24877. PMID: 33629336.Meo SA, Bukhari IA, Akram J, Meo AS, Klonoff DC. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines. Eur Rev Med Pharmacol Sci. 2021 Feb; 25 (3): 1663–1669. DOI: 10.26355/eurrev_202102_24877. PMID: 33629336.Ríos E, Medrano S, Martínez M, Novella C, Marcos E, Fernández JJ, Delgado-Iribarren A, Culebras E. Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose. Vaccines (Basel). 2022 Aug 25; 10 (9): 1397. DOI: 10.3390/vaccines10091397. PMID: 36146475; PMCID: PMC 9504129.Ríos E, Medrano S, Martínez M, Novella C, Marcos E, Fernández JJ, Delgado-Iribarren A, Culebras E. Analysis of Adverse Effects of COVID-19 Vaccines in Spain following Booster Dose. Vaccines (Basel). 2022 Aug 25; 10 (9): 1397. DOI: 10.3390/vaccines10091397. PMID: 36146475; PMCID: PMC 9504129.Yuemiao Zhang, Xupu Ma, Guanghong Yan et al. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. J. Lancet. Dec.2022 Vol.54. https://doi.org/10.1016/j.eclinm.2022.101680Yuemiao Zhang, Xupu Ma, Guanghong Yan et al. Immunogenicity, durability, and safety of an mRNA and three platform-based COVID-19 vaccines as a third dose following two doses of CoronaVac in China: A randomised, double-blinded, placebo-controlled, phase 2 trial. J. Lancet. Dec.2022 Vol.54. https://doi.org/10.1016/j.eclinm.2022.101680Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, Hu C, Selvachandran S, Antonelli M, Murray B, Canas LS, Molteni E, Graham MS, Modat M, Joshi AD, Mangino M, Hammers A, Goodman AL, Chan AT, Wolf J, Steves CJ, Valdes AM, Ourselin S, Spector TD. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect Dis. 2021 Jul; 21 (7): 939–949. DOI: 10.1016/s1473–3099(21)00224–3. Epub 2021 Apr 27. PMID: 33930320; PMCID: PMC 8078878.Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, Hu C, Selvachandran S, Antonelli M, Murray B, Canas LS, Molteni E, Graham MS, Modat M, Joshi AD, Mangino M, Hammers A, Goodman AL, Chan AT, Wolf J, Steves CJ, Valdes AM, Ourselin S, Spector TD. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: A prospective observational study. Lancet Infect Dis. 2021 Jul; 21 (7): 939–949. DOI: 10.1016/s1473–3099(21)00224–3. Epub 2021 Apr 27. PMID: 33930320; PMCID: PMC 8078878.Jarynowski A, Semenov A, Kamiński M, Belik V. Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning. J Med Internet Res. 2021 Nov 29; 23 (11): e30529. DOI: 10.2196/30529. PMID: 34662291; PMCID: PMC 8631420.Jarynowski A, Semenov A, Kamiński M, Belik V. Mild Adverse Events of Sputnik V Vaccine in Russia: Social Media Content Analysis of Telegram via Deep Learning. J Med Internet Res. 2021 Nov 29; 23 (11): e30529. DOI: 10.2196/30529. PMID: 34662291; PMCID: PMC 8631420.Global Advisory Committee on Vaccine Safety: Statement on Myocarditis and Pericarditis. Oct 2021 [Available from: https://www.who.int/news/item/27–10–2021-gacvs-statement-myocarditis-pericarditis-covid-19-mrna-vaccines-updatedGlobal Advisory Committee on Vaccine Safety: Statement on Myocarditis and Pericarditis. Oct 2021 [Available from: https://www.who.int/news/item/27–10–2021-gacvs-statement-myocarditis-pericarditis-covid-19-mrna-vaccines-updatedPrice AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N Engl J Med. 2022; 386 (20): 1899–909.Price AM, Olson SM, Newhams MM, Halasa NB, Boom JA, Sahni LC, et al. BNT162b2 Protection against the Omicron Variant in Children and Adolescents. N Engl J Med. 2022; 386 (20): 1899–909.Shafiq A, Salameh MA, Laswi I, Mohammed I, Mhaimeed O, Mhaimeed N, Mhaimeed N, Paul P, Mushannen M, Elshafeey A, Fares A, Holroyd S, Zakaria D. Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review. J Clin Pharmacol. 2022 Mar; 62 (3): 291–303. DOI: 10.1002/jcph.2017. Epub 2022 Feb 10. PMID: 34921562.Shafiq A, Salameh MA, Laswi I, Mohammed I, Mhaimeed O, Mhaimeed N, Mhaimeed N, Paul P, Mushannen M, Elshafeey A, Fares A, Holroyd S, Zakaria D. Neurological Immune-Related Adverse Events After COVID-19 Vaccination: A Systematic Review. J Clin Pharmacol. 2022 Mar; 62 (3): 291–303. DOI: 10.1002/jcph.2017. Epub 2022 Feb 10. PMID: 34921562.Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination: A systematic review. J Neurol Sci. 2021 Sep 15; 428: 117607. DOI: 10.1016/j.jns.2021.117607. Epub 2021 Aug 3. PMID: 34365148; PMCID: PMC 8330139.Sharifian-Dorche M, Bahmanyar M, Sharifian-Dorche A, Mohammadi P, Nomovi M, Mowla A. Vaccine-induced immune thrombotic thrombocytopenia and cerebral venous sinus thrombosis post COVID-19 vaccination: A systematic review. J Neurol Sci. 2021 Sep 15; 428: 117607. DOI: 10.1016/j.jns.2021.117607. Epub 2021 Aug 3. PMID: 34365148; PMCID: PMC 8330139.Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20; 397 (10275): 671–681. DOI: 10.1016/s0140–6736(21)00234–8. Epub 2021 Feb 2. Erratum in: Lancet. 2021 Feb 20; 397 (10275): 670. PMID: 33545094; PMCID: PMC 7852454.Logunov DY, Dolzhikova IV, Shcheblyakov DV, Tukhvatulin AI, Zubkova OV, Dzharullaeva AS, Kovyrshina AV, Lubenets NL, Grousova DM, Erokhova AS, Botikov AG, Izhaeva FM, Popova O, Ozharovskaya TA, Esmagambetov IB, Favorskaya IA, Zrelkin DI, Voronina DV, Shcherbinin DN, Semikhin AS, Simakova YV, Tokarskaya EA, Egorova DA, Shmarov MM, Nikitenko NA, Gushchin VA, Smolyarchuk EA, Zyryanov SK, Borisevich SV, Naroditsky BS, Gintsburg AL; Gam-COVID-Vac Vaccine Trial Group. Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: An interim analysis of a randomised controlled phase 3 trial in Russia. Lancet. 2021 Feb 20; 397 (10275): 671–681. DOI: 10.1016/s0140–6736(21)00234–8. Epub 2021 Feb 2. Erratum in: Lancet. 2021 Feb 20; 397 (10275): 670. PMID: 33545094; PMCID: PMC 7852454.Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015 Aug 26; 33 (36): 4398–405. DOI: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22. PMID: 26209838; PMCID: PMC 4632204.Shimabukuro TT, Nguyen M, Martin D, DeStefano F. Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS). Vaccine. 2015 Aug 26; 33 (36): 4398–405. DOI: 10.1016/j.vaccine.2015.07.035. Epub 2015 Jul 22. PMID: 26209838; PMCID: PMC 4632204.Крюков Е. В., Тришкин Д. В., Иванов А. М. [и др.]. Эпидемиологическое исследование коллективного иммунитета против новой коронавирусной инфекции среди разных групп военнослужащих. Вестник Российской академии медицинских наук. 2021. Т. 76. № 6. С. 661–668.Kryukov E. V., Trishkin D. V., Ivanov A. M. [and etc.]. An epidemiological study of herd immunity against a new coronavirus infection among different groups of military personnel. Bulletin of the Russian Academy of Medical Sciences. 2021. V. 76. No. 6. P. 661–668.Намазова-Баранова Л.С., Федосеенко М. В., Шахтахтинская Ф. Ч., Калюжная Т. А., Солошенко М. А., Толстова С. В., Сельвян А. М., Привалова Т. Е., Тимошкова С. Д., Мельникова А.А., Горелов А.В., Плоскирева А. А., Мустафина И. З., Мелехина Е. В., Усенко Д. В., Понежева Ж.Б., Омарова Х. Г. Эффективность и безопасность иммунизации пептидной вакциной для профилактики инфекции, вызванной SARS-CoV-2: проспективное исследование среди медицинских работников. Вопросы современной педиатрии. 2022; 21 (2): 83–94. DOI: https://doi.org/10.15690/vsp.v21i2.2386Namazova-Baranova L.S., Fedoseenko M. V., Shakhtakhtinskaya F. Ch., Kalyuzhnaya T. A., Soloshenko M. A., Tolstova S. V., Selvyan A. M., Privalova T. E., Timoshkova S. D., Melnikova A. A., Gorelov A.V., Ploskireva A. A., Mustafina I.Z., Melekhina E. V., Usenko D. V., Ponezheva Zh.B., Omarova X. G. Efficacy and safety of immunization with a peptide vaccine for the prevention of SARS-CoV-2 infection: a prospective study in healthcare workers. Questions of modern pediatrics. 2022; 21 (2): 83–94. DOI: https://doi.org/10.15690/vsp.v21i2.2386Беспятых Ю. А., Господарик А. В., Шанский Я. Д. Особенности иммунного ответа у лиц, вакцинированных препаратов «КОВИВАК». Проблемы медицинской микологии 2022. Т. 24. № 2. С. 48.Bespyatykh Yu.A., Gospodarik A. V., Shansky Ya. D. Features of the immune response in persons vaccinated with ‘KOVIVAK’ preparations. Problems of Medical Mycology 2022. V. 24. No. 2. P. 48.Господарик А. В., Мейдман Е. О., Шанский Я. Д., Беспятых Ю. А. Особенности иммунного ответа у лиц, вакцинированных препаратов «КОВИВАК». В книге: Материалы научно-практических конференций в рамках VIII Российского конгресса лабораторной медицины (РКЛМ 2022). Сборник тезисов. Москва, 2022. С. 180.Gospodarik A. V., Meidman E. O., Shansky Ya.D., Bespyatykh Yu. A. Features of the immune response in persons vaccinated with ‘KOVIVAK’ preparations. In the book: Proceedings of scientific and practical conferences within the framework of the VIII Russian Congress of Laboratory Medicine (RKLM 2022). Collection of abstracts. Moscow, 2022, p. 180.

The authors declare that there are no conflicts of interest present.